milestone payments
Zymeworks Pivots to Royalty-Driven Model After Strong Ziihera Data in Gastric Cancer
Zymeworks; royalty-driven model; Ziihera; gastric cancer; HER2; biologics; milestone payments; stock buyback; biotech strategy; Jazz Pharmaceuticals; regulatory filing
Regeneron and ModeX Forge Potential $1 Billion+ Collaboration to Develop Multispecific Antibody Drugs
Regeneron; ModeX Therapeutics; multispecific antibodies; MSTAR platform; biotechnology deal; upfront payment; milestone payments; immunology; oncology; metabolic diseases; collaboration; OPKO Health
GSK Secures Exclusive Rights to Syndivia’s Preclinical Prostate Cancer ADC in $357 Million Deal
GSK; Syndivia; ADC; prostate cancer; metastatic castration-resistant prostate cancer; exclusive licensing; oncology pipeline; GeminiMab technology; milestone payments; preclinical asset
Roche Inks $80M Upfront Deal for Hansoh’s Cancer ADC HS-20110
Roche; Hansoh Pharmaceutical; ADC; HS-20110; CDH17; colorectal cancer; solid tumors; licensing deal; upfront payment; milestone payments; royalties
Behind-the-Scenes Details of 89bio’s $2.4B Deal with Roche
Roche; 89bio; pegozafermin; MASH; liver disease; contingent value rights; biotech acquisition; pharmaceuticals; deal structure; milestone payments
Halozyme to Acquire Elektrofi for $750 Million, Expanding Drug Delivery Capabilities
Halozyme Therapeutics; Elektrofi; acquisition; drug delivery; Hypercon; biologics; subcutaneous delivery; milestone payments; microparticle technology; Q4 2025
Glenmark Pharma Signs $1.1 Billion Deal with Hengrui for HER2-Targeted Antibody-Drug Conjugate
Glenmark; Hengrui Pharma; Trastuzumab Rezetecan; HER2-targeting antibody drug conjugate; oncology; exclusive license; $1.1 billion deal; cancer therapy; milestone payments; royalties
VectorY Strikes $1.2B Option and License Pact with Shape Therapeutics for Brain-Penetrant Gene Therapy Delivery
VectorY Therapeutics; Shape Therapeutics; SHP-DB1; adeno-associated virus (AAV) capsid; brain-penetrant delivery; gene therapy; neurodegenerative diseases; Huntington’s disease; Alzheimer’s disease; biobucks; pipeline; milestone payments; vectorized antibodies
Novartis Expands Degrader-Focused Collaboration with Monte Rosa Through Major Molecular Glue Deal
Novartis; Monte Rosa Therapeutics; molecular glue degraders; MRT-6160; VAV1 protein; immune-mediated diseases; drug discovery; collaboration; milestone payments; AI/ML-enabled product engine
Novartis Again Partners with Argo Biopharma in $5.2B+ RNAi Cardiovascular Deal
Novartis; Argo Biopharma; RNA interference (RNAi); siRNA; cardiovascular pipeline; ANGPTL3; dyslipidemia; biotech collaboration; drug development; milestone payments